Interpace Biosciences Inc. (IDXG) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Interpace Biosciences Inc. (NASDAQ: IDXG) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $5.59 (-2.23% 1D, market cap $22.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 485 tracked Industrials issuers, IDXG ranks #94 in composite RQD confidence.
Within the Industrials sector (Diversified Equities), IDXG carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of 16.2%. By comparison, JBDI (JBDI Holdings Limited) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $22.5M) and BHST (BioHarvest Sciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, IDXG leads on earnings multiple (N/A) while IDXG leads on capital efficiency (16.2% ROIC).
Per IDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001054102), Interpace Biosciences Inc. generated $38.7M in revenue (-17.5% YoY), $24.6M in net income, and $5.5M in free cash flow against $33.8M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 68% of 52W Range • RSI-14 at 49.8 (NEUTRAL RANGE)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
Capital intensity & 10.5% operating margin leave 11 pts on the table
Even with a 63/100 (C) score, IDXG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.8% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.87) or 200D SMA ($2.79) invalidates the momentum regime and cuts Target Base ($5.72) toward Bear Floor ($4.46).
Interpace Biosciences Inc. (IDXG) dropped -2.23% to $5.59, trading at 68% of its 52-week range ($0.81 – $7.8). Solid 62% profit margin (16% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Yahoo! Finance Canada report covering Interpace Biosciences Inc. (IDXG) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Interpace Biosciences Inc. (IDXG) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Interpace Biosciences Inc. (IDXG) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Interpace Biosciences Inc. (IDXG) market action, institutional positioning, and fundamental catalysts.
Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 millionExpected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026Expected year-over-year growth of approximately 15% t
Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid
Q1 Revenue of $9.0 millionQ1 Income from Continuing Operations of $0.8 millionQ1 Thyroid volume year-over-year increase of 10%Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE
PARSIPPANY, NJ, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”), an emerging leader in enabling personalized medicine, today announced that it will effect a 1-fo
Q2 Revenue of $9.1 millionQ2 Income from Continuing Operations of $0.3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid revenue of $36.1
Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free balance sheet and positive Net Inco
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -17.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IDXG today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IDXG. Explore sector supply chains on /butterfly.
Across 485 tracked Industrials securities in the Roarable RQD universe, Interpace Biosciences Inc. (IDXG) ranks #94 by composite RQD confidence (63/100, grade C) and #429 by equity capitalization ($22.7M). Within this direct 5-issuer industry benchmark cohort, IDXG leads on earnings valuation at N/A trailing P/E, while IDXG leads on capital efficiency and profitability with 16.2% ROIC and 62.3% gross margin. IDXG currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IDXG
ACTIVE
Interpace Biosciences Inc. | C | 63/100 | — | 62.3% | 16.2% | -2.23% | $22.7M | Benchmark Subject |
| JBDI JBDI Holdings Limited | D | 46/100 | — | 49.9% | — | -2.08% | $22.5M | /jbdi-vs-idxg → |
| BHST BioHarvest Sciences Inc. | E | 34/100 | — | 59.3% | -35.0% | 0.00% | $37.6M | /bhst-vs-idxg → |
| RML Resolution Minerals Ltd | D | 47/100 | — | — | — | -2.54% | $43.0M | /rml-vs-idxg → |
| STKE Sol Strategies Inc. | D | 44/100 | — | — | — | -3.91% | $48.6M | /stke-vs-idxg → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Interpace Biosciences Inc. (IDXG) reported GAAP revenue of $38.7M (-17.5% vs. FY2024 revenue of $46.9M , and -3.3% cumulative change since FY2023) , GAAP net income of $24.6M, operating cash flow of $5.8M, and free cash flow of $5.5M (+45.2% YoY). On the balance sheet, IDXG closed FY2025 with $33.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $38.7M | $24.6M | $5.8M | $5.5M | $33.8M | — |
| FY2024 (FY) | 2024-12-31 | $46.9M | $6.7M | $4.6M | $3.8M | $14.8M | — |
| FY2023 (FY) | 2023-12-31 | $40.0M | $2.0M | $3.8M | $3.8M | — | — |
As of 2026-11-03, Interpace Biosciences Inc. (NASDAQ: IDXG) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $5.59 (-2.23% 1D, market cap $22.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 485 tracked Industrials issuers, IDXG ranks #94 in composite RQD confidence.
Within the Industrials sector (Diversified Equities), IDXG carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of 16.2%. By comparison, JBDI (JBDI Holdings Limited) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $22.5M) and BHST (BioHarvest Sciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, IDXG leads on earnings multiple (N/A) while IDXG leads on capital efficiency (16.2% ROIC).
Per IDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001054102), Interpace Biosciences Inc. generated $38.7M in revenue (-17.5% YoY), $24.6M in net income, and $5.5M in free cash flow against $33.8M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
IDXG last traded at $5.59 (-2.23% on volume of 502 shares), positioning the stock -4.77% below its 50-day simple moving average ($5.87) and +100.36% above its 200-day simple moving average ($2.79). Across its 52-week range of $0.81 to $7.80, IDXG sits at the 68.4% percentile with a 14-day RSI of 49.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($4.96 to $6.22).
Why IDXG Stock dropped -2.23% Today — RQD Quant Desk Flash. Solid 62% profit margin (16% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Per the Roarable RQD rating, IDXG scores 64 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine at 9 of 20 (ROIC 16.2%; FCF yield 23.6%); Whale 13F Flow at 11 of 20 (institutional accumulation and options positioning); Insider Conviction at 15 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 16 of 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).
For a prospective investor, the profile is mixed. The strongest pillars are macro fit and insider conviction, while the Fundamental Cash Engine carries the lowest score relative to its weight, meaning the cash-generation case is the weakest part of the rating despite the high FCF yield figure. The FCF yield of 23.6% is an upside-driver signal on paper, but per the SEC financials, FY 2025 free cash flow was $5.5M against a $4.1M operating income line, and the figures do not establish durability. Valuation tradeoffs center on a small market capitalization ($23.2M) and an EV/EBITDA of 4.7, which can indicate a low multiple but also reflects the limited scale and thin liquidity evidenced by a trading volume of 5,107. The Forensic Balance Sheet score of 13 of 20 suggests a moderate, not distressed, financial posture, though cash of $2.5M per the SEC financials is small in absolute terms. The rating does not constitute personalized advice; it summarizes the source-derived evidence.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $38.7M | $4.1M | $24.6M | N/A | $5.5M | $2.5M | N/A |
| FY 2024 | $46.9M | $8.1M | $6.7M | N/A | $3.8M | $1.5M | N/A |
| FY 2023 | $40.0M | $4.0M | $2.0M | N/A | $3.8M | N/A | N/A |
Per the SEC financials, revenue declined from $46.9M in FY 2024 to $38.7M in FY 2025, while reported net income of $24.6M in FY 2025 sits well above operating income of $4.1M, a gap the source data does not explain. The reported net margin of 63.5% in the market data is consistent with that unusual divergence and warrants verification. ROIC is 16.2% per the market data. The Altman Z-Score of 2.5 and Piotroski F-Score of 6 of 9, per the Roarable RQD rating, together point to a moderate balance sheet, and Debt/Equity is 0.5; the debt figure itself is N/A in the filings.
Per the recent news data, four items are tagged to IDXG, all with a YELLOW light and MARKET WIRE impact label. The most substantive item is a headline reporting pricing for a 3.1M share offering at $6-$7 amid Nasdaq listing plans, which signals dilution and capital-raising activity. The remaining three items are calendar and chart pages with generic summaries and no company-specific detail. The market data shows a single-session change of 15.56%. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Interpace Biosciences Inc. (IDXG) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Interpace Biosciences Inc. (IDXG) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Interpace Biosciences Inc. (IDXG) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Interpace Biosciences Inc. (IDXG) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Interpace Biosciences Inc. (IDXG) market action, institutional positioning, and fundamental catalysts.
Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 millionExpected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026Expected year-over-year growth of approximately 15% t
Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid
Q1 Revenue of $9.0 millionQ1 Income from Continuing Operations of $0.8 millionQ1 Thyroid volume year-over-year increase of 10%Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE
PARSIPPANY, NJ, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”), an emerging leader in enabling personalized medicine, today announced that it will effect a 1-fo
Welcome to the IDXG (Interpace Biosciences Inc.) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Diversified Equities. Bulls point to capital efficiency (16.2% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on IDXG, but look at what you are paying: current EV/EBITDA multiples with 62.3% gross margins. Unless Interpace Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on IDXG, the market is fixating on short-term headline noise in Diversified Equities and ignoring the balance sheet and cash flow trajectory. At $5.72 (52-wk range $0.81 - $7.80), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).